Study of Fostriecin for Cancer Treatment
Author Information
Author(s): Jong R S de, Mulder N H, Uges D R A, Sleijfer D Th, Höppener F J P, Groen H J M, Willemse P H B, Graaf W T A van der, Vries E G E de
Primary Institution: University Hospital Groningen
Hypothesis
Can fostriecin, a topoisomerase II inhibitor, be safely administered and show pharmacokinetic properties in cancer patients?
Conclusion
Fostriecin has a short plasma half-life and did not show significant tumor responses, but further dose escalation may be warranted.
Supporting Evidence
- Fostriecin was administered intravenously over 60 minutes for five days at four-week intervals.
- The predominant toxicities included elevated liver transaminases and serum creatinine.
- Mean fostriecin plasma half-life was 0.36 hours initially and 1.51 hours terminally.
- No tumor responses were observed in the study.
Takeaway
Doctors tested a new cancer drug called fostriecin to see how it works in the body, but it didn't help patients' tumors shrink.
Methodology
Fostriecin was given intravenously over 60 minutes for five days at four-week intervals, with dose escalation from 2 mg/m² to 20 mg/m².
Limitations
The maximum tolerated dose was not reached due to drug supply issues, and no tumor responses were observed.
Participant Demographics
Patients with small-cell lung cancer were included in the study.
Statistical Information
Confidence Interval
95% CI, 0–0.76 h (initial); 95% CI, 0.41–2.61 h (terminal)
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website